

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Beck, et al.

Customer No.: 51957

Serial No: 10/800,992

Filed: March 15, 2004

For: PRESERVED CYCLODEXTRIN-
CONTAINING COMPOSITIONS

Group Art Unit: 1614

Examiner: JAG0E, DONNA A.

Confirmation No.: 2049

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered. No fee is believed due in connection with this communication in accordance with 37 C.F.R. § 1.97(c) and 37 C.F.R. § 1.97(e). However, if Applicant is in error, please charge any fees that may be due in connection with this Information Disclosure Statement and to refund any overpayment to Deposit Account No. 01-0885.

Date: September 24, 2007

Respectfully submitted,

/Brent A. Johnson/

Brent A. Johnson

Registration No. 51,851

Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson

Allergan, Inc. (T2-7H)

2525 Dupont Drive

Irvine, CA 92612

Telephone: 714/246-4348/Facsimile: 714/246-4249